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Heart failure (HF) remains a leading cause of morbidity and mortality
in both men and women in both sides of the Atlantic. Patients hospi-
talized with HF are at high risk for recurrent events, hospitalizations,
and cardiovascular death. In the last decades, an impressive number
of randomized controlled trials has established the paramount role
of several pharmacologic and non-pharmacologic strategies to
reduce all-cause mortality for patients with HF and left ventricular
functional impairment. Thanks to these investigations, European
and American scientific societies have developed guidelines that
provide evidence-based recommendations for treating acute and
chronic HF,1,2 including b-blockers, angiotensin-converting enzyme
(ACE)-inhibitors, angiotensin receptor blockers (ARBs), aldosterone
antagonists, hydralazine/isosorbide dinitrate, implantable cardiov-
eter defibrillators, and cardiac resynchronization therapy. Neverthe-
less, the use of these therapies in daily clinical practice remains
inconsistent.
The problem of poor application of evidence-based therapies as
well as poor compliance to drug prescriptions has been discussing
in-depth in recent years in North America,3 whereas it still barely
faced in Europe. As a consequence, the potential magnitude of ben-
efits of optimal implementation of evidence-based therapies in HF in
European countries remains unclear. One should consider, however,
that determining the respective gains that optimal application of each
evidence-based therapy may provide is essential in prioritizing per-
formance improvement efforts and planning future strategies.
The current study
In the current issue, De Blois et al. report important data from the
Norwegian Heart Failure Registry.4 The authors aimed at assessing
the adherence to guidelines for ACE-inhibitors, ARB, andb-blockers
and the possible association of ACE-inhibitors or ARB, b-blockers
and statins in 5761 hospital outpatients who were diagnosed with
HF of any aetiology over a 10-year period. Statistical analysis
showed that Norwegian patients had a high adherence to treatment
according to guidelines. Cox regression analysis showed that
b-blockers, higher doses of ACE-inhibitors, and statins were signifi-
cantly related to improved survival. As honestly recognized by the
authors,4 this study suffers from limitations intrinsic in clinical regis-
tries. Missing data and selection bias are important drawbacks, but
one should also keep in mind that statistical associations do not
prove cause–effect relationships and that confounders can affect
statistical computations substantially. As a matter of fact, however,
the use of clinical registries is an important tool for determining the
effectiveness of a therapy in routine clinical practice.5 Observational
studies allow for the inclusion of broader populations of patients than
randomized controlled trials and therefore can provide clinicians and
patients with a more realistic expectation for outcomes in real-world
environments. When carefully applied, a registry-based research
constitutes a reliable and even invaluable source for informing
routine clinical practice, and are essential to translating findings
from randomized controlled trials into high-quality evidence that
can guide routine clinical practice.5 Accordingly, the study by De
Blois et al. allows us to derive two reliable, novel conclusions.4
First, the outcome of HF patients improves consistently when the ad-
herence to the use of drugs indicated by European Society of Cardi-
ology guidelines is high. Second, an increased survival can be obtained
if patients are given b-blockers and statins, whereas ACE-inhibitors
are effective only if doses ≥50% of the maximal recommended
target are prescribed and ARBs have not effect on survival in the
real world.
Clinical implications and future
perspectives
The results of the study by De Blois et al. confirm previous observa-
tions by North American investigators that adherence to evidence-
based, guideline-recommended therapies may have a crucial role in
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survival improvement.6 Noteworthy, the expected gains would be
much smaller if class I therapies, as it is the case of ACE-inhibitors,
are used at low doses rather than at if doses ≥50% of the maximal
recommended target. Establishing the potential benefits of optimal
implementation of these therapies is of considerable importance
to underscore growing European efforts to improve the use of
evidence-based therapies in patients with HF. Indeed, newereffective
approaches to improve the use of evidence-based, guideline-
recommended therapies for HF are urged for European healthcare
system. Implementations of programs aimed at assessing the adher-
ence to scientific guidelines are in place in Europe in association
with the ESC and HFA and in the USA.7 Numerous studies have
demonstrated that adherence to clinical guidelines is associated
with a better patient outcome, including significant reductions in
30-day readmissions. In conclusion, timehas comethat, given the sub-
stantial HF burden, the European scientific community makes extra
efforts to ensure optimal implementation of each evidence-based,
guideline-recommended therapy.
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